1. Home
  2. DFS vs BIIB Comparison

DFS vs BIIB Comparison

Compare DFS & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DFS
  • BIIB
  • Stock Information
  • Founded
  • DFS 1985
  • BIIB 1978
  • Country
  • DFS United States
  • BIIB United States
  • Employees
  • DFS N/A
  • BIIB N/A
  • Industry
  • DFS Finance: Consumer Services
  • BIIB Biotechnology: Pharmaceutical Preparations
  • Sector
  • DFS Finance
  • BIIB Health Care
  • Exchange
  • DFS Nasdaq
  • BIIB Nasdaq
  • Market Cap
  • DFS 36.6B
  • BIIB 28.6B
  • IPO Year
  • DFS 2007
  • BIIB 1991
  • Fundamental
  • Price
  • DFS $150.52
  • BIIB $189.55
  • Analyst Decision
  • DFS Buy
  • BIIB Buy
  • Analyst Count
  • DFS 20
  • BIIB 23
  • Target Price
  • DFS $136.06
  • BIIB $273.59
  • AVG Volume (30 Days)
  • DFS 1.1M
  • BIIB 1.4M
  • Earning Date
  • DFS 10-16-2024
  • BIIB 10-30-2024
  • Dividend Yield
  • DFS 1.87%
  • BIIB N/A
  • EPS Growth
  • DFS N/A
  • BIIB N/A
  • EPS
  • DFS 12.39
  • BIIB 7.94
  • Revenue
  • DFS $11,686,000,000.00
  • BIIB $9,672,000,000.00
  • Revenue This Year
  • DFS N/A
  • BIIB N/A
  • Revenue Next Year
  • DFS N/A
  • BIIB N/A
  • P/E Ratio
  • DFS $12.14
  • BIIB $23.87
  • Revenue Growth
  • DFS 11.97
  • BIIB N/A
  • 52 Week Low
  • DFS $79.04
  • BIIB $181.31
  • 52 Week High
  • DFS $152.90
  • BIIB $268.30
  • Technical
  • Relative Strength Index (RSI)
  • DFS 66.75
  • BIIB 44.64
  • Support Level
  • DFS $141.52
  • BIIB $186.61
  • Resistance Level
  • DFS $149.97
  • BIIB $194.13
  • Average True Range (ATR)
  • DFS 3.28
  • BIIB 3.58
  • MACD
  • DFS 0.76
  • BIIB 0.81
  • Stochastic Oscillator
  • DFS 87.35
  • BIIB 60.19

About DFS Discover Financial Services

Discover Financial Services is a bank operating in two distinct segments: direct banking and payment services. The company issues credit and debit cards and provides other consumer banking products including deposit accounts and personal loans. It also operates the Discover, Pulse, and Diners Club networks. The Discover network is the fourth-largest payment network in the United States as ranked by overall purchase volume, and Pulse is one of the largest ATM networks in the country.

About BIIB Biogen Inc.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Share on Social Networks: